Nuvation Bio to receive $150 million in royalty interest financing and $50 million in debt upon U.S. FDA approval of taletrectinib, with access to additional $50 million in debt at the Company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results